Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic Interaction Study to Evaluate the Pharmacokinetic Effect of Rifabutin on BMS-626529, the Active Moiety of BMS-663068, With and Without Ritonavir in Healthy Subjects

Next Previous
Search
Trial Profile

Pharmacokinetic Interaction Study to Evaluate the Pharmacokinetic Effect of Rifabutin on BMS-626529, the Active Moiety of BMS-663068, With and Without Ritonavir in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fostemsavir (Primary) ; Rifabutin; Ritonavir
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb; ViiV Healthcare

    • Most Recent Events

    • 08 Oct 2020 Results of two phase 1 drug-drug interaction studies, presented at the 15th International Congress on Drug Therapy and HIV Infection.
    • 08 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 May 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top